

=> D HIS

(FILE 'HOME' ENTERED AT 22:06:56 ON 20 APR 2003)

FILE 'USPATFULL' ENTERED AT 22:07:03 ON 20 APR 2003

L1 0 S 'L1-L5' (W) ADENOVIR?  
L2 77 S 'L1-L5' (P) ADENOVIR?  
L3 57 S 'E2' (P) L2

FILE 'WPIDS' ENTERED AT 22:24:43 ON 20 APR 2003

L4 1 S WO9412649/PN  
L5 0 S L3 AND L4  
L6 0 S "E2" AND L4  
L7 1 S 'E4' AND L4  
L8 1 S L7 (P) ADENOVIR?

FILE 'USPATFULL' ENTERED AT 22:28:25 ON 20 APR 2003

L9 20 S L2 NOT L3  
L10 4206 S NONFUNCTIONAL  
L11 16 S L10 AND L2  
L12 37 S ('E2' OR 'E4' OR 'L1' OR 'L2' OR 'L3' OR 'L4' OR 'L5') (P) NONF  
L13 25 S L12 AND ADENOVIR?

FILE 'MEDLINE' ENTERED AT 22:43:00 ON 20 APR 2003

L14 15 S ('E2' OR 'E4' OR 'L1' OR 'L2' OR 'L3' OR 'L4' OR 'L5') (P) NONF  
L15 36 S NONFUNCTIONAL AND ADENOVIR?  
L16 57535 S ('E2' OR 'E4' OR 'L1' OR 'L2' OR 'L3' OR 'L4' OR 'L5')  
L17 885 S L16 AND ADENOVIR?  
L18 2 S L17 AND NONFUNCTIONAL  
L19 117 S L17 AND DEFECT?

FILE 'CONFSCI' ENTERED AT 23:11:31 ON 20 APR 2003

E WILSON/AU  
E WILSON J/AU  
E WILSON J M/AU  
L20 62 S E3  
L21 4 S L20 AND ADENOVIR?

=>

ENTER DISPLAY FORMAT (BIB):ALL

L21 ANSWER 3 OF 4 CONFSCI COPYRIGHT 2003 CSA  
AN 94:9185 CONFSCI  
DN 94021222  
TI Safety and efficacy of recombinant **adenoviruses** for lung  
directed gene therapy in nonhuman primates  
AU Engelhardt, J.; Simon, R.; Zepeda, M.; Yang, Yiping; **Wilson, J.M.**  
CS Inst. for Human Gene Ther., Univ. Pennsylvania, Philadelphia,  
Pennsylvania, USA  
SO John Wiley & Sons, Inc., Subscription Department 9th Floor, 605 Third  
Avenue, New York, NY 10158-0012, USA; Telephone: (212) 850-6543,  
Abstracts, Pediatric Pulmonology, Supplement 9, September 1993, ISSN:  
8755-6863 Paper No. S16.4.  
Meeting Info.: 934 5002: Seventh Annual North American Cystic Fibrosis  
Conference (9345002). Dallas, TX (USA). 13-16 Oct 1993. Cystic Fibrosis  
Foundation.  
DT Conference  
FS DCCP  
LA English  
CC 3500 CLINICAL MEDICINE; 4500 EXPERIMENTAL MEDICINE

could be pur

4/21/03

art — ORDER — 14

L19 ANSWER 75 OF 117 MEDLINE  
AN 95004602 MEDLINE  
DN 95004602 PubMed ID: 7522742  
TI Inactivation of E2a in recombinant **adenoviruses** improves the  
prospect for gene therapy in cystic fibrosis.  
AU Yang Y; Nunes F A; Berencsi K; Gonczol E; Engelhardt J F; Wilson J M  
CS Institute for Human Gene Therapy, University of Pennsylvania Medical  
Center, Philadelphia.  
SO NATURE GENETICS, (1994 Jul) 7 (3) 362-9.  
Journal code: 9216904. ISSN: 1061-4036.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199411  
ED Entered STN: 19941222  
Last Updated on STN: 19960129  
Entered Medline: 19941117  
AB Although first generation recombinant **adenoviruses**, deleted of  
sequences spanning E1a and E1b, have been useful for in vivo applications  
of gene therapy, expression of the recombinant gene has been transient and  
often associated with the development of inflammation. We show that with  
first generation **adenovirus**-mediated gene transfer to the mouse  
lung, viral proteins are expressed leading to destructive cellular immune  
responses and repopulation of the lung with nontransgene containing cells.  
Second generation E1 deleted viruses further crippled by a temperature  
sensitive mutation in the E2a gene were associated with substantially  
longer recombinant gene expression and less inflammation. Stable  
expression of human CF transmembrane conductance regulator has been  
achieved in lungs of CF mice instilled with a second generation virus.